फेफड़ों का कैंसर (non-small cell)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
कौन जुड़ सकता हैवयस्क
उम्र18+ साल
किस तरह का अध्ययनPhase 3: सामान्य इलाज से तुलना
यह क्या test करता हैएक medicine
कौन जुड़ सकता है और कौन नहीं, इसकी पूरी लिस्ट रजिस्ट्री में है। ट्रायल टीम से पूछें, या हमें लिखें और हम इसे आसान शब्दों में समझा देंगे।
कहाँ जाना है
इस ट्रायल के लिए भारत में 18 अस्पताल मरीजों को ले रहे हैं।
Hemato Oncology Clinicअहमदाबाददिशाएं ↗
KLES Dr. Prabhakar Kore Hospital & M.R.Cबेलागावीदिशा ↗
SRV Hospitalsबेंगलुरुदिशा ↗
All India Institute of Medical Sciencesभुवनेश्वररास्ता ↗
Ashwin Hospitalकोयंबटूरदिशा ↗
Nizam's Institute of Medical Sciencesहैदराबाददिशा ↗
Krishna Institute of Medical Sciences - Karadकराडदिशा ↗
Kolhapur Cancer Centre Private Limitedकोल्हापुरदिशा ↗
HCG Manavata Cancer CentreNashikरास्ता ↗
Advanced Centre for Treatment Research and Education in Cancerनवी मुंबईदिशा ↗
Jawaharlal Institute Of Postgraduate Medical Education And Researchपुडुचेरीरास्ता ↗
Grant Medical Foundation - Ruby Hall Clinicपुणेदिशा ↗
Sahyadri Super Speciality Hospitalपुणेदिशा ↗
Lifepoint Multispeciality Hospitalपुणेदिशा ↗
Regional Cancer Centre - Thiruvananthapuramतिरुवनंतपुरमदिशा ↗
Pacific Medical College & HospitalउदयपुरDirections ↗
Tata Memorial Centre - Homi Bhabha Cancer HospitalवाराणसीDirections ↗
Mahatma Gandhi Cancer Hospital and Research Instituteविशाखापट्टनमDirections ↗
रजिस्ट्री समरी (तकनीकी)
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Sponsor: Eli Lilly and Company
NCT06119581 on ClinicalTrials.gov
Last updated on the registry 7 Oct 2026 · read by us 20 Oct 2026